Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics

Background: In the context of hormone receptor positive, HER2 negative Metastatic breast cancer (MBC), CDK 4/6 inhibitors (CDK4/6i) combined with endocrine therapy represent the standard first-line treatment, improving Progression-Free Survival (PFS) and Overall Survival (OS). Despite these benefits...

Descripció completa

Dades bibliogràfiques

Autors principals:	Lorenzo Foffano, Alessandra Franzoni, Elisabetta Molteni, Fabiola Giudici, Arianna Dri, Debora Basile, Linda Cucciniello, Silvia Buriolla, Claudia Noto, Stefania Russo, Elena Nascimbeni, Silvia Bolzonello, Brenno Pastò, Serena Della Rossa, Lorenzo Allegri, Marta Bonotto, Alessandro Marco Minisini, Barbara Belletti, Giuseppe Damante, Lorenzo Gerratana, Fabio Puglisi
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-09-01
Col·lecció:	Translational Oncology
Matèries:	Metastatic breast cancer Liquid biopsy Fragmentomics Circulating tumor DNA
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S1936523325001871
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!